

研究成果の刊行に関する一覧表

書籍

| 著者氏名 | 論文タイトル名 | 書籍全体の編集者名 | 書籍名 | 出版社名 | 出版地 | 出版年 | ページ |
|-------------------|-------------------|-----------|----------------------|-------|-----|------|------------|
| <u>泉並木</u> | HCV抗体が毎年陽性になります | | きょうの健康 | NHK出版 | 東京 | 2023 | 106 |
| 泉並木、加藤真三、栗原毅、川口巧 | 肝機能がみるみる強まる食べ方飲み方 | 上野陽之助 | 肝機能がみるみる強まる食べ方飲み方 | 文響社 | 東京 | 2023 | 19-38 |
| 瓦谷英人、 <u>吉治仁志</u> | 肝硬変 | | 病態生理と症例から学薬物療法・治療ガイド | 文光堂 | | 2023 | 40:114-120 |

雑誌

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|--|---|---------------|-------|---------|------|
| Okushin K, <u>Tateishi R</u> , Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, Kudo M, <u>Koike K.</u> | The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL). | Sci Rep. | 14(1) | 2826 | 2024 |
| Kanai S, Fujiwara H, Mizuno S, Kishikawa T, Nakatsuka T, Hamada T, Tanaka M, Arita J, Nakai Y, Isayama H, Kasuga M, <u>Tateishi R</u> , Tateishi K, Ushiku T, Hasegawa K, <u>Koike K.</u> , Fujishiro M. | Increased expression of TNFRSF14 and LIGHT in biliary epithelial cells of patients with primary sclerosing cholangitis. | DigLiver Dis. | 56(2) | 305-311 | 2024 |
| Sato M, Moriyama M, Fukumoto T, | Development of a transformer model for predicting the | Hepatol Int. | 18(1) | 131-137 | 2024 |

| | | | | | |
|---|--|---------------------|--------|-----------|------|
| Yamada T, Wake T, Nakagomi R, Nakatsuka T, Minami T, Uchino K, Enooku K, Nakagawa H, Shiina S, <u>Koike K</u> , Fujishiro M, <u>Tateishi R</u> . | prognosis of patients with hepatocellular carcinoma after radiofrequency ablation. | | | | |
| Soeda K, Sasako T, Enooku K, Kubota N, Kobayashi N, Ikushima YM, Awazawa M, Bouchi R, Toda G, Yamada T, Nakatsuka T, <u>Tateishi R</u> , Kakiuchi M, Yamamoto S, Tatsuno K, Atarashi K, Suda W, Honda K, Aburatani H, Yamauchi T, Fujishiro M, Noda T, <u>Koike K</u> , Kadowaki T, Ueki K. | Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. | Nat Commun. | 14(1) | 6584 | 2023 |
| Nakatsuka T, <u>Tateishi R</u> , Sato M, Fujishiro M, <u>Koike K</u> . | Agile scores are a good predictor of liver-related events in patients with NAFLD. | J Hepatol. | 79(3) | e126-e127 | 2023 |
| Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, Minami T, <u>Tateishi R</u> , Ichida A, Arita J, Hasegawa K, <u>Koike K</u> , Fujishiro M, Nakagawa H. | Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma. | Hepatol Commun. | 7(8) | e0209 | 2023 |
| Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, <u>Tateishi R</u> , Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, <u>Koike K</u> . | Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. | Am J Gastroenterol. | 118(8) | 1365-1372 | 2023 |
| Wake T, <u>Tateishi R</u> , Moriyama M, Fukumoto T, Yamada T, | Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study. | Hepatol Res. | 53(7) | 675-680 | 2023 |

| | | | | | |
|---|--|----------------------------|-------------------------------|-------|------|
| Nakagomi R, Nakatsuka T, Sato M, Minami T, Uchino K, Nakagawa H, Shiina S, <u>Koike K</u> , Fujishiro M. | | | | | |
| Minami T, Sato M, Toyoda H, Yasuda S, Yamada T, Nakatsuka T, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Tanaka Y, Otsuka M, Ohki T, Arai M, Asaoka Y, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Nakagomi R, Akamatsu M, Mitsui H, Fujie H, Ogura K, Uchino K, Yoshida H, Hanajiri K, Wada T, Kurai K, Maekawa H, Kondo Y, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Yotsuyanagi H, Moriya K, Kumada T, Fujishiro M, <u>Koike K</u> , <u>Tateishi R</u> . | Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals. | J Hepatol. | Epub ahead of print. | | 2023 |
| Okushin K, Yamana H, <u>Tateishi R</u> , Sato M, Tsutsumi T, Matsui H, Fushimi K, Yasunaga H, <u>Koike K</u> , Fujishiro M. | Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database. | BMC Gastroenterol. | 23(1) | 218 | 2023 |
| Lee SW, Huang DQ, Bettencourt R, Ajmera V, Tincopa M, Nouredin N, Amangurbanova M, Siddiqi H, Madamba E, Majzoub AM, Nayfeh T, Tamaki N, <u>Izumi N</u> , Nakajima A, Yoneda M, Idilman R, Gumussoy M, Oz DK, Erden A, | Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality. | Aliment Pharmacol Ther. | 59 | 80-88 | 2024 |

| | | | | | |
|---|--|---------------------|-----|-----------|------|
| Loomba R. | | | | | |
| Kim DY, Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, <u>Izumi N</u> , Huyen NN, Chow PK, Mohamed R, Chan SL, Tanwandee T, Lee TY, Hai TTN, Yang T, Lee WC, Chan HLY. | Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. | Clin Mol Hepatol. | 29 | 277-292 | 2023 |
| Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, <u>Izumi N</u> , Itoi T, Unno M, Ohtsuka M, Okusaka T, Kadoya M, Kudo M, Kumada T, Kokudo N, Sakamoto M, Sakamoto Y, Sakurai H, Takayama T, Nakashima O, Nagata Y, Hatano E, Harada K, Murakami T, Yamamoto M. Liver Cancer Study Group of Japan | Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. | Liver Cancer | 23 | 290-314 | 2023 |
| Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, Chuang WL, Janssen HLA, Fung S, <u>Izumi N</u> , Abdurakhmanov D, Jabłkowski M, Celen MK, Ma X, Caruntu F, Flaherty JF, Abramov F, Wang H, Camus G, Osinusi A, Pan CQ, Shalimar D, Seto WK, Gane E. | Long-term Treatment with Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. | Am J Gastroenterol. | 119 | 486-99 | 2023 |
| Kim BK, Bergstrom J, Loomba R, Tamaki N, <u>Izumi N</u> , Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Truong E, Yang JD, Noureddin M, Allen AM, Loomba R, | Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study. | Hepatology. | 78 | 1858-1866 | 2023 |

| | | | | | |
|---|---|-------------------------------|-----|---------|------|
| Ajmera V. | | | | | |
| Huang DQ, Nouredin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, Gidener T, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, <u>Izumi N</u> , Yoneda M, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Allen AM, Nouredin M, Loomba R. | Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. | Lancet Gastroenterol Hepatol. | 8 | 829-836 | 2023 |
| Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, <u>Izumi N</u> . | Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study. | Liver Cancer. | 12 | 321-338 | 2023 |
| Kuroda H, Oguri T, Kamiyama N, Toyoda H, Yasuda S, Imajo K, Suzuki Y, Sugimoto K, Akita T, Tanaka J, Yasui Y, Kurosaki M, <u>Izumi N</u> , Nakajima A, Fujiwara Y, Abe T, Kakisaka K, Matsumoto T, Kumada T. | Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis. | Radiology | 309 | e230341 | 2023 |
| Lim YS, Chan HLY, Ahn SH, Seto WK, Ning Q, Agarwal K, Janssen HLA, Pan CQ, Chuang WL, <u>Izumi N</u> , Fung S, Shalimar, Brunetto M, Hui AJ, Chang TT, Lim SG, Abramov F, Flaherty JF, Wang H, Yee LJ, | Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B. | JHEP Rep. | 13 | 100847 | 2023 |

| | | | | | |
|--|---|-------------------------|----|-----------|------|
| Kao JH, Gane E, Hou J, Buti M. | | | | | |
| Ishido S, Tamaki N, Takahashi Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Kurosaki M, <u>Izumi N.</u> | Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. | BMC Gastroenterol. | 23 | 211 | 2023 |
| Huang DQ, Tamaki N, Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, <u>Izumi N.</u> , Kim BK, Sinn DH. | Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. | Hepatology | 77 | 1746-1756 | 2023 |
| Ishido S, Tamaki N, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, <u>Izumi N.</u> | Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B. | JGH Open | 21 | 567-571 | 2023 |
| Noureddin N, Ajmera V, Bergstrom J, Bettencourt R, Huang DQ, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, <u>Izumi N.</u> , Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, | MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses. | Aliment Pharmacol Ther. | 58 | 856-865 | 2023 |

| | | | | | |
|--|---|-------------------|------|---------|---------|
| Loomba R. | | | | | |
| Takaki S, Kurosaki M, Mori N, Tsuji K, Ochi H, Marusawa H, Nakamura S, Tada T, Narita R, Uchida Y, Akahane T, Kondo M, Kusakabe A, Furuta K, Kobashi H, Arai H, Nonogi M, Tamada T, Hasebe C, Ogawa C, Sato T, Tamaki N, Yasui Y, Tsuchiya K, Izumi N. | Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. | Invest New Drugs. | 41 | 340-349 | 2023 |
| Yamada-Shimizu M, Tamaki N, Kurosaki M, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Nobusawa T, Matsumoto H, Keitoku T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, <u>Izumi N.</u> | A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease. | Intern Med. | 10 | 2248-23 | 2023 |
| Hayakawa Y, Tamaki N, Nakanishi H, Kurosaki M, Tanaka Y, Inada K, Ishido S, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Okamoto R, <u>Izumi N.</u> | Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy. | Intern Med. | 62 | 973-978 | 2023 |
| Shimakami T, Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, Tanaka J, <u>Kanto T*.</u> | Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan. | J Gastroenterol | 58 | 257-267 | 2023 |
| <u>Kudo M*</u> , Tsuchiya | Impact of bevacizumab being | Liver Cancer | DOI: | | 2023(Ep |

| | | | | | |
|--|---|--------------|-------------------------------|-----------|-----------------------|
| K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M | skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: An exploratory analysis of the Phase III IMbrave150 study. | | 10.11 59/00 0535 501 | | ub ahead of print) |
| Abou-Alfa GK [†] , Lau G [†] , Kudo M [†] , Chan SL [†] , Kelly RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B, fro the HIMALAYA Investigators | Plain language summary of results from the HIMALAYA study: tremelimumab and durvalumab for the treatment of participants with unresectable hepatocellular carcinoma (liver Cancer). | Future Oncol | 19(38) | 2505-2516 | 2023 |
| <u>Kudo M</u> | Current therapeutic strategies for hepatocellular carcinoma in Japan. | Liver Cancer | 12(6) | 497-509 | 2023 |
| Qin S [†] , Chen M [†] , Cheng AL [†] , Kaseb AO [†] , Kudo M [†] , Lee HC [†] , Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH, for the IMbrave050 investigators | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. | Lancet | 402 (10415) | 1835-1847 | 2023 |
| <u>Kudo M</u> | Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the Phase III IMbrave150 study | Liver Cancer | 12(5) | 479-493 | 2023 |
| <u>Kudo M</u> | All stages of hepatocellular | Liver Cancer | 12(5) | 189-197 | 2023 |

| | | | | | |
|---|--|----------------------------|----------------------|-----------|------|
| | carcinoma patients benefit from systemic therapy combined with locoregional therapy. | | | | Aug |
| <u>Kudo M</u> | Drug-off criteria in patients with hepatocellular carcinoma who achieved clinical complete response after combination treatment with immunotherapy and locoregional therapy. | Liver Cancer | 12(4) | 289-296 | 2023 |
| <u>Kudo M</u> | Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma. | Hepatobiliary Surg Nutr | 12(3) | 435-439 | 2023 |
| <u>Kudo M*</u> , Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki K, Jia J, Lencioni R | IMbrave 150: Efficacy and safety of atezolizumab plus bevacizumab vs sorafenib in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: an exploratory analysis of the Phase III study. | Liver Cancer | 12(3) | 238-250 | 2023 |
| <u>Kudo M</u> | Adjuvant atezolizumab-bevacizumab after resection or ablation for hepatocellular carcinoma. | Liver Cancer | 12(3) | 189-197 | 2023 |
| <u>Kudo M</u> | The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma. | Hepatobiliary Surg Nutr | 12(2) | 256-260 | 2023 |
| Dalbeni A, Lombardi R, Henrique M, Zoncapè M, Pennisi G, Petta S, <u>Tateishi R</u> , Keklikkiran C, Colecchia A, Sacerdoti D, Mantovani A, Ravaioli F. | Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis. | Hepatology | 79(5) | 1107-1116 | 2024 |
| Takaoka S, Hamada T, Takahara N, Saito K, Endo G, Hakuta R, Ishida K, Ishigaki K, Kanai S, Kurihara K, Oyama H, Saito T, Sato T, Suzuki T, Suzuki Y, Tange S, Tokito Y, <u>Tateishi R</u> , Nakai Y, Fujishiro M. | Skeletal muscle status and survival among patients with advanced biliary tract cancer. | Int J Clin Oncol. | 29(3) | 297-308 | 2024 |
| Qin XY, Shirakami Y, Honda M, Yeh SH, Numata K, Lai YY, Li CL, Wei F, Xu Y, Imai K, Takai | Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. | Int J Cancer. | Epub ahead of print. | | 2024 |

| | | | | | |
|--|---|-------------------------|---------------|------------------|-------------|
| <p>K, Chuma M, Komatsu N, Furutani Y, Gailhouste L, Aikata H, Chayama K, Enomoto M, <u>Tateishi R</u>, Kawaguchi K, Yamashita T, Kaneko S, Nagaoka K, Tanaka M, Sasaki Y, Tanaka Y, Baba H, Miura K, Ochi S, Masaki T, Kojima S, Matsuura T, Shimizu M, Chen PJ, Moriwaki H, Suzuki H.</p> | | | | | |
| <p>Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, Miki D, Kurosaki M, Hiasa Y, Sakamori R, Kawada N, Yamashita T, Suda G, Yatsuhashi H, Yoshiji H, Kato N, Takami T, Nakao K, Matsuura K, Asahina Y, Itoh Y, <u>Tateishi R</u>, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Ueno Y, Akuta N, Miyazaki M, Nozaki Y, Kabayama M, Sobue S, Moriuchi A, Miyaki T, Kodama T, Tatsumi T, Yamada T, Takehara T.</p> | <p>Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.</p> | <p>J Gastroenterol.</p> | <p>58(12)</p> | <p>1211-1221</p> | <p>2023</p> |
| <p>Nakatsuka T, Nakagawa H, Uchino K, Rokutan H, Tanaka M, Moriyama M, Fukumoto T, Yamada T, Wake T, Nakagomi R, Sato M, Minami T, Kudo Y, Ushiku T, Fujishiro M, <u>Tateishi R</u>.</p> | <p>Clinical utility of postablation liver tumor biopsy and possibility of gene mutation analysis.</p> | <p>Hepatol Res.</p> | <p>53(11)</p> | <p>1117-1125</p> | <p>2023</p> |

| | | | | | |
|--|---|---------------|--------|---------|------|
| Kawaguchi Y, <u>Tateishi R</u> , Kokudo N, Hasegawa K. | Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma. | Liver Cancer. | 12(5) | 494-496 | 2023 |
| Iijima H, Kudo M, Kubo S, Kurosaki M, Sakamoto M, Shiina S, <u>Tateishi R</u> , Osamu N, Fukumoto T, Matsuyama Y, Murakami T, Takahashi A, Miyata H, Kokudo N. | Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015). | Hepatol Res. | 53(10) | 895-959 | 2023 |
| Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, <u>Tateishi R</u> ; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. | Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). | Hepatol Res. | 53(5) | 383-390 | 2023 |
| Okushin K, <u>Tateishi R</u> , Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, <u>Hasegawa K</u> , Eguchi Y, Kanto T, Yoshiji H, Izumi N, Kudo M, Koike K. | The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL). | Sci Rep. | 14(1) | 2826 | 2024 |
| <u>Hasegawa K</u> , Takemura N, | Clinical Practice Guidelines for Hepatocellular Carcinoma: The | Hepatol Res. | 53(5) | 383-390 | 2023 |

| | | | | | |
|--|--|---------------------|-------|-----------|------|
| Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. | Japan Society of Hepatology 2021 Version (5th JSH-HCC Guidelines). | | | | |
| Kawaguchi Y, Tateishi R, Kokudo N, <u>Hasegawa K.</u> | Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma. | Liver Cancer | 12(5) | 494-496 | 2023 |
| Yorioka N, Namisaki T, Shibamoto A, Suzuki J, Kubo T, Iwai S, Tomooka F, Tanaka M, Takeda S, Fujimoto Y, Enomoto M, Muarata K, Inoue T, Tsuji Y, Fujinaga Y, Nishimura N, Kitagawa K, Takaya H, Kaji K, Kawaratani H, Akahane T, Mitoro A, Yamazaki M, <u>Yoshiji H.</u> | Changes in Coagulation and Fibrinolytic Factors in Patients with Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan | In Vivo | 37 | 1226-1235 | 2023 |
| Moriya K, Saeki K, Nishimura N, Sato S, Sawada Y, Takaya H, Kaji K, Kawaratani H, Namisaki T, Akahane T, <u>Yoshiji H.</u> | Zinc Supplementation and an Improved Quality of Life in Patients with Autoimmune Hepatitis | Intern Med. | 63 | 145-152 | 2023 |
| Yoshiji H | "Management of cirrhotic ascites: Seven-step treatment | Hepatology Research | 53 | 794-805 | 2023 |

| | | | | | |
|---|---|----------------------|--------|-----------|------|
| | protocol based on the Japanese evidence-based clinical practice guidelines for liver cirrhosis 2020" | | | | |
| Shibamoto A, Namisaki T, Suzuki J, Kubo T, Iwai S, Tomooka F, Takeda S, Fujimoto Y, Inoue T, Tanaka M, Koizumi A, Yorioka N, Matsuda T, Asada S, Tsuji Y, Fujinaga Y, Nishimura N, Sato S, Takaya H, Kitagawa K, Kaji K, Kawaratani H, Akahane T, Mitoro A, <u>Yoshiji H.</u> | Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic Cirrhosis | Diagnostics (Basel). | 13 | 2218 | 2023 |
| Shibamoto A, Namisaki T, Suzuki J, Kubo T, Iwai S, Tomooka F, Takeda S, Fujimoto Y, Enomoto M, Murata K, Inoue T, Tsuji Y, Fujinaga Y, Nishimura N, Kitagawa K, Takaya H, Kaji K, Kawaratani H, Akahane T, Mitoro A, <u>Yoshiji H.</u> | Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosis | Hepatology Research | 53 | 713-722 | 2023 |
| <u>吉治仁志</u> | 肝硬変診療ガイドラインを日常診療にどう生かすか | 京都消化器医会会報 第9号 | 39 | 23-29 | 2023 |
| <u>赤羽たけみ</u> , <u>吉治仁志</u> | 肝硬変診療ガイドラインを読み解く—Annual Review を踏まえて | 臨床消化器内科 | 38 | 1239-1246 | 2023 |
| Okushin K, Tateishi R, Hirakawa S, <u>Tachimori H.</u> , Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, Kudo M, Koike K. | The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL). | Sci Rep | 14 (1) | 2826 | 2024 |